Merck says Keytruda boosted overall survival in phase 3 ovarian cancer trial and cut death risk in bladder cancer combo data. Read more here.

By Padmanabhan Ananthan Feb 23 (Reuters) - Merck said on Monday it would create a separate division for its cancer business, anchored by its top-selling drug Keytruda, as the U.S. drugmaker braces for ...

Merck is splitting its pharmaceutical business into two units, separating its oncology operations from its non-cancer drugs ...

Merck & Co. said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Keytruda for certain patients with ...

The drugmaker is splitting up its Human Health business before patent protection on its blockbuster treatment Keytruda expires in two years.

The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.